Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 8/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.42 |
| ▸ | MAP3K6 | O95382 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 7/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4522322 | 0.82 | GRM5 (0.40) | GRM5MAPTCCNA2CDK2CCNA1 | |
| SCHEMBL4522150 | 0.79 | GRM5 (0.42) | GRM5MAPTCCNA2CDK2CCNA1 | |
| SCHEMBL4520887 | 0.74 | GRM5 (0.44) | GRM5MAPTDYRK1A | |
| SCHEMBL4515632 | 0.72 | GRM5 (0.43) | GRM5MAPT | |
| SCHEMBL17255742 | 0.72 | ATM (0.40) | MAP3K5MAP3K7MAP3K6CDK2 | |
| SCHEMBL4517225 | 0.71 | BRD4 (0.40) | GRM5MAPT | |
| SCHEMBL4528975 | 0.69 | GRM5 (0.44) | GRM5MAPT | |
| SCHEMBL11562966 | 0.69 | GRM5 (0.51) | GRM5MAPT | |
| SCHEMBL28402729 | 0.68 | MAPT (0.57) | GRM5MAPT | |
| SCHEMBL29501822 | 0.68 | MAPT (0.57) | GRM5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| CN-101460478-A | Novel bi-aryl amines | NOVARTIS AG (CH) | 2009-06-17 | — | — | CN | disclosed |
| EP-2004624-A1 | NOVEL BI-ARYL AMINES | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113276-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113276-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NAT1, MAOB, CYP2B6 | MAP3K5 2527/4885MAP3K7 2513/4885MAP3K6 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.